Vaibhav Global Ltd.    
31 May 2020, 05:23PM
1103.85
1.87%
Earnings Call Transcript - Q4FY20 for Vaibhav Global

Conference Call with Vaibhav Global Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript.

Rakesh Jhunjhunwala    
31 May 2020, 05:00PM
Rakesh Jhunjhunwala starts comments to Jubilant management with complaint, ends with congratulations

Rakesh Jhunjhunwala, who holds over 4.4% of Jubilant Life Sciences in his portfolio (a stake worth approximately Rs. 310 crore), participated in the company's earnings discussion. Jhunjhunwala started the conversation with a complaint - that he had to wait on the line for twenty minutes to join the call.

Jhunjhunwala's main questions however, centered around dividend payouts and cash reserves. 

"On what basis is the board declaring a dividend?" Rakesh Jhunjhunwala asked. " Do you have a defined dividend policy? 10% dividend payout is ridiculous."

"We are trying to conserve cash because of the COVID situation," CEO Pramod Yadav responded, "We have high debt, twice our EBITDA, so we are looking to reduce our debt."  

Jhunjhunwala's second question was around the company's cash reserves. "Why are you holding such large amounts of cash? You have around Rs.1,200 crore in cash." 

"The main cash amount is in the US", Yadav answered, "and we will be using it in repayments".

He may have started with a complaint, but Jhunjhunwala ended his comments with a congratulations "on a fine quarter performance". Jubilant Life has seen record profits in FY20 and improvement in margins. During the year the company says it reduced its net debt by Rs. 514 crore, and is looking to reduce it further with cash flows.

Despite the tough Covid19 situation, the company has kept its facilities operational, and demand conditions, it says, remain stable. With lifting of lockdowns in the US, business has resumed to 70% of normal levels. 

Capex plans are being reined in, management says, to conserve cash. It expects to have the capex amount to be around $15 million - but it may be lesser depending on how the pandemic evolves. Jubilant's Nanjangud plant had operations suspended in early March due to positive covid cases. The company has now received permission to restart the plant, and Jubilant expects to partly mitigate the impact by increasing API production for a few high-demand products.

Jubilant recently announced a licensing agreement to register, manufacture and sell Gilead's COVID19 treatment drug, remdesivir, which is currently under trials. "We are working towards initiating production of the drug by July 2020, subject to all regulatory approvals." Chairman Shyam Bhartia said. 

KPIT Technologies Ltd.    
31 May 2020, 04:06PM
49.25
4.90%
Earnings Call Transcript - Q4FY20 for KPIT Technologies

Conference Call with KPIT Tech Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook.  Listen to the full earnings transcript

Highlights from Mr. Ravi Pandit, Chairman of KPIT Technologies

First complete full year as an automative solutions focused company. Revenue growth of over 14% - industry leading growth. EBITDA growth was 35% Margin increased from 11.5% to 13%. EBITDA growth of Q4 over Q3 was 2%. While there was negative YoY growth for PAT, QoQ growth was positive. 

Growth in top 20 customers YoY was 20%. Emphasis on key customers has given results. Attrition has also come down from 25% last year to about 15%. Higher profitability has converted into higher cash. Ended FY20 with Rs 328 crore cash baalnce.

Power train and autonomous are the drivers of growth and contributed to 60% of revenues. Our goal is to maximize wallet share from customers, by maintaining quality and speed in catering to our customers. 

Our focus is also to conserve cash, and improve liquidity further. We expect Q1 to see a 15% drop in revenues, on the basis of how customers have responded to the pandemic. Salary impact will be adjusted downward since a portion of salaries is variable, and we have also increased the variable component in salaries. 

We are cautious about FY21 owing to uncertainty due to the current disruption and possibility of a relapse of the pandemic globally. Hence, we refrain from giving any outlook for FY21 at this juncture, but we expect H2 to be better than H1. We are seeing some good big deals, so overall we are pretty optimistic about the future. We expect the current disruption in the automotive industry to create new opportunities in the medium term. H1FY21 revenues will be impacted and significant effect will be in Q1FY21. New deal wins benefit will be seen from H2FY21.

We believe the automotive industry and mobility in the broader sense will continue to grow, with potentially more demand in self-driven and fully autonomous cars. We have invested in these technologies and will continue to do so. Our focus on fewer but high quality services should deliver good yields in the years to come. 

Polycab India Ltd.    
31 May 2020, 01:59PM
679.40
4.56%
Earnings Call Transcript - Q4FY20 for Polycab India

Conference Call with Polycab India Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript

 

default
NCC Ltd.    
31 May 2020, 11:54AM
22.95
-2.34%
Earnings Call Transcript - Q4FY20 for NCC Limited

Conference Call with NCC Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript

default
Symphony Ltd.    
30 May 2020, 06:40PM
897.35
10.00%
Earnings Call Transcript - Q4FY20 for Symphony Limited

Conference Call with Symphony Limited Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript

default
Dilip Buildcon Ltd.    
30 May 2020, 06:30PM
260.45
1.36%
Earnings Call Transcript - Q4FY20 for Dilip Buildcon

Conference Call with Dilip Buildcon Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript

Jubilant Life Sciences Ltd.    
30 May 2020, 06:26PM
442.15
1.84%
Earnings Call Transcript - Q4FY20 for Jubilant Life Sciences

Conference Call with Jubilant Life Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript

Metropolis Healthcare Ltd.    
30 May 2020, 06:21PM
1384.95
4.77%
Earnings Call Transcript - Q4FY20 for Metropolis Healthcare

Conference Call with Metropolis Healthcare Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript.

Rain Industries Ltd.    
29 May 2020, 11:02PM
72.35
4.10%
Earnings Call Transcript - Q1CY20 for Rain Industries

Conference Call with Rain Industries Management and Analysts on Q1CY20 Earnings Performance and Outlook. Listen to the full earnings transcript